Biotinylated Human CLEC12A/MICL/CLL-1 Protein
Catalog No: CLEC12A-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CLEC12A/MICL/CLL-1 Protein is expressed in HEK293 cells with a His tag at the N-terminus and Avi tag at the C-terminus. It contains amino acid residues His65-Ala265 (UniProt accession: Q5QGZ9-2).
Product Details
- Molecular Aliases
- MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2
- Protein Length
- His65-Ala265
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 26.4 kDa. Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human CLEC12A on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human CLEC12A is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human CLEC12A, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-CLEC12A Antibody, hFc Tag with the EC50 of 29.6ng/ml determined by ELISA.
Background
CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.
References
- Bill M, Aggerholm A, Kjeldsen E, Roug AS, Hokland P, Nederby L. Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy. Br J Haematol. 2019 Mar;184(5):769-781. doi: 10.1111/bjh.15711. Epub 2018 Dec 5. PMID: 30520015.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.